Tuesday, October 20, Pfizer and BioNTech announced the start of combined Phase 1 and Phase 2 clinical trials of their mRNA vaccine candidate in Japan.
In a statement, the firm said that the study will recruit 160 people aged from 20 to 85. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.
The firm has said it may confirm if the vaccine is effective as soon as this month, but also needs safety data from a global trial of 44,000 people that will not be available until next month.
Japan has pledged to secure enough vaccine supply for its entire population by the middle of 2021. In addition to Pfizer, it has struck deals on supplies with AstraZeneca Plc and other overseas makers of vaccine candidates.
Clinical trials of AstraZeneca’s experimental COVID-19 vaccine have resumed in Japan after being put on hold over the illness of a British volunteer.